Here, AKT has been suggested as a therapeutic target for cancer,[54] and there has been success in clinical trial by combinatorial therapy using a chemotherapeutic agent and an AKT inhibitor in metastatic breast cancer.[55] This suggests possible clinical applications of this target in other cancer types, including bladder cancer. This evidence concerns the gene AKT1 and urinary bladder carcinoma.